Litigation Details for Indivior Inc. v. Mylan Technologies Inc. (N.D.W. Va. 2017)

Indivior Inc. v. Mylan Technologies Inc. (N.D.W. Va. 2017)

Docket	1:17-cv-00157	Date Filed	2017-09-14
Court	District Court, N.D. West Virginia	Date Terminated	2017-09-27
Cause	35:271 Patent Infringement	Assigned To	Irene Patricia Murphy Keeley
Jury Demand	None	Referred To
Patents	9,687,454
Link to Docket	External link to docket

Details for Indivior Inc. v. Mylan Technologies Inc. (N.D.W. Va. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-09-14				External link to document
2017-09-14	1		#0424-2426786. (Attachments: # 1 Exhibit A - Patent No. 9,687,454 B2)[Keeley](cnd) (Additional attachment(… COMPLAINT FOR PATENT INFRINGEMENT against Mylan N.V., Mylan Pharmaceuticals Inc., Mylan Technologies… 27 September 2017 1:17-cv-00157 835 Patent - Abbreviated New Drug Applications (ANDA)	External link to document

Indivior Inc. v. Mylan Technologies Inc. Litigation Summary and Patent Analysis

Last updated: August 21, 2026

Indivior Inc. v. Mylan Technologies Inc., No. 1:17-cv-00157, was a Hatch-Waxman patent dispute over Mylan’s abbreviated new drug application for generic buprenorphine/naloxone sublingual film, the generic equivalent of Suboxone Film. The case centered on U.S. Patent No. 8,603,514, which claimed polymeric drug films with defined polymer-content ranges. The Federal Circuit ultimately affirmed the invalidity of the asserted ’514 patent claims for lack of written description, removing the principal patent barrier to Mylan’s generic launch.[1]

What drug and ANDA were at issue in Indivior v. Mylan?

The litigation concerned Suboxone Film, a sublingual film containing buprenorphine and naloxone for opioid-dependence treatment.

Item	Detail
Brand	Suboxone Film
Active ingredients	Buprenorphine hydrochloride and naloxone hydrochloride
Dosage form	Sublingual polymeric film
Innovator	Indivior Inc.
Generic applicant	Mylan Technologies Inc.
Regulatory pathway	ANDA under the Hatch-Waxman Act
ANDA	Mylan ANDA No. 209657
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:17-cv-00157
Principal patent	U.S. Patent No. 8,603,514
Federal Circuit result	Invalidity affirmed on written-description grounds

Mylan’s ANDA sought approval to market a generic buprenorphine/naloxone film before the expiration of Indivior’s listed patents. Indivior filed suit after receiving Mylan’s Paragraph IV certification that the relevant patents were invalid, unenforceable, or not infringed.

What patents protected Suboxone Film in the Mylan litigation?

The principal patent issue was U.S. Patent No. 8,603,514, titled “Drug-containing polymeric films and methods of making same.” The patent covered pharmaceutical films containing active ingredients dispersed in a polymer matrix.

The asserted claims required, among other limitations, a polymer component present at approximately 40% to 60% by weight. The Federal Circuit held that the patent specification did not adequately describe that claimed range.

Indivior’s broader Suboxone Film patent estate also included later patents directed to film compositions, manufacturing techniques, dosage forms, and related formulation characteristics. The Mylan case should not be treated as a ruling that every Suboxone-related patent was invalid. Its most consequential holding concerned the asserted claims of the ’514 patent.

U.S. Patent No. 8,603,514

Field	Detail
Patent number	8,603,514
Technology	Buprenorphine/naloxone polymeric film
Relevant claim limitation	Polymer concentration of approximately 40% to 60% by weight
Core legal issue	Written-description support for the claimed range
District court result	Asserted claims held invalid
Federal Circuit result	Affirmed
Commercial consequence	Mylan was no longer blocked by the ’514 patent

The written-description dispute arose because the specification disclosed several narrower polymer ranges and examples but did not adequately support the full claimed 40% to 60% range. The Federal Circuit rejected the argument that disclosure of separate, narrower ranges necessarily demonstrated possession of the broader claimed range.[1]

When did Indivior v. Mylan begin, and what were the major litigation dates?

Date	Event
February 2, 2017	Indivior filed the District of Delaware action
2017-2018	Mylan litigated invalidity and infringement defenses under the Hatch-Waxman framework
2018-2019	The district court addressed the validity of the ’514 patent claims
2019	The district court held the relevant ’514 claims invalid for lack of written description
2020	The Federal Circuit affirmed the written-description ruling
June 2023	The ’514 patent’s listed patent term was reached, based on publicly available patent-term records

The action was part of a larger wave of litigation involving Indivior’s Suboxone Film patents and ANDA filers, including challenges by Dr. Reddy’s Laboratories and other generic manufacturers.

What was the Paragraph IV challenge in the Mylan case?

Mylan filed an ANDA containing a Paragraph IV certification against Indivior’s listed patents. A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.

Indivior’s patent suit triggered the Hatch-Waxman 30-month stay of FDA approval, subject to the statutory framework and any intervening court orders. The litigation therefore affected both FDA approval timing and the date on which Mylan could commercially market its generic film.

The central defense was not limited to noninfringement. Mylan challenged the validity of the ’514 patent, arguing that the patent claims covered a polymer range that was not supported by the original disclosure. That argument prevailed at both the district court and Federal Circuit levels.

Why did the Federal Circuit invalidate Indivior’s ’514 patent claims?

The Federal Circuit applied the written-description requirement of 35 U.S.C. § 112. A patent specification must demonstrate that the inventor possessed the claimed invention as of the filing date. Possession can be shown through examples, technical descriptions, or disclosure of a representative portion of the claimed genus. The disclosure must correspond to the actual scope of the claims.[1]

The relevant claims covered films containing approximately 40% to 60% polymer by weight. The specification disclosed several polymer ranges, including narrower ranges that did not collectively establish possession of the full 40% to 60% interval.

The court’s analysis focused on the difference between:

1. Disclosing individual points or narrower subranges; and
2. Disclosing the entire broader range later claimed.

The Federal Circuit held that the patent did not provide sufficient support for the broader range. The court therefore affirmed invalidity of the asserted claims under the written-description requirement.

Why the ruling mattered commercially

The decision weakened Indivior’s ability to rely on the ’514 patent as a launch-blocking asset. The ruling also created a precedent for challenging pharmaceutical patents that claim broad numerical ranges not adequately supported by the specification.

The case illustrates a recurring pharmaceutical patent risk: a formulation patent can appear commercially valuable because it covers a marketed product, yet fail if its claims extend materially beyond the technical disclosure filed with the application.

What was the FDA status of Mylan’s generic Suboxone Film?

Mylan pursued FDA approval through ANDA No. 209657. The ANDA route required Mylan to demonstrate pharmaceutical equivalence and bioequivalence to the reference product, rather than repeat the full clinical-development program used for Suboxone.

The FDA’s approval process was linked to the patent certifications in Mylan’s ANDA. Once the relevant litigation barrier was removed, Mylan could proceed under the applicable FDA approval and market-entry rules.

Suboxone Film is a small-molecule drug product. Biosimilar law under the Biologics Price Competition and Innovation Act was not applicable. The relevant competitive pathway was generic ANDA approval, not a biosimilar application under section 351(k) of the Public Health Service Act.

What was the litigation outcome in Indivior v. Mylan?

The decisive outcome was that the asserted claims of the ’514 patent were held invalid for lack of written description. The Federal Circuit affirmed the district court’s judgment.[1]

Issue	Outcome
Hatch-Waxman suit	Filed by Indivior against Mylan
Paragraph IV certification	Mylan challenged patent validity and infringement
’514 patent validity	Asserted claims invalid
Written description	Failed for the claimed 40%-60% polymer range
Federal Circuit review	District court judgment affirmed
Generic launch barrier	Removed for the invalidated claims
Patent estate effect	Reduced protection for the relevant Suboxone Film formulation

The decision was more important for patent validity than for claim construction. The Federal Circuit’s ruling did not establish a broad rule that all polymer-film patents were defective. It held that this specification did not adequately support these claims.

What patent litigation affected Suboxone generic entry?

Indivior faced a coordinated generic challenge to Suboxone Film. The company litigated against multiple ANDA applicants, including Mylan, Dr. Reddy’s Laboratories, and other generic manufacturers.

The competitive litigation involved several categories of patents:

• Composition patents covering buprenorphine/naloxone films.
• Formulation patents covering polymer concentration and film structure.
• Manufacturing patents covering casting, drying, and production methods.
• Method-of-use patents associated with opioid-dependence treatment.
• Later patents addressing product characteristics and manufacturing controls.

The invalidity ruling against the ’514 patent reduced the value of one of Indivior’s principal formulation patents. Generic companies could still face other listed patents, regulatory requirements, commercial launch risks, and potential litigation over separate products or patent claims.

How strong was Indivior’s patent estate after the Mylan ruling?

The estate was mixed.

Strengths

Indivior had a commercially relevant portfolio covering the product’s dosage form, manufacturing process, and formulation characteristics. Multiple patents could increase litigation cost and delay generic entry even when one patent was vulnerable.

The portfolio also benefited from the practical difficulty of designing an equivalent sublingual film. Generic applicants had to match release characteristics, film performance, drug loading, stability, and bioequivalence requirements.

Weaknesses

The ’514 decision exposed written-description risk in broad numerical formulation claims. Claims that cover broad polymer ranges must be supported by a specification that demonstrates possession of the full range. Disclosing only selected examples or narrower subranges may not be sufficient.

The ruling also reduced the expected value of the ’514 patent in settlement negotiations. A patent held invalid after appellate review cannot support a conventional launch-barrier settlement in the same way as an unchallenged or upheld patent.

Did the case involve a settlement agreement?

The Mylan action is principally associated with adjudication of the ’514 patent’s validity rather than a final settlement that preserved the patent as an effective barrier.

Indivior entered into separate agreements and litigation resolutions with other generic manufacturers in the broader Suboxone patent campaign. Those agreements should be analyzed separately because settlement terms, launch dates, authorized-generic provisions, and patent releases differed by defendant.

A settlement in another Suboxone case does not establish the result in the Mylan docket. The Mylan outcome was driven by the invalidity judgment and appellate affirmance.

What generic entry risks remained after the ’514 decision?

After invalidation of the asserted ’514 claims, the principal risks shifted from that patent to other parts of Indivior’s portfolio and to regulatory execution.

Risk category	Effect on Mylan or later generic entrants
Remaining formulation patents	Could support separate infringement claims
Manufacturing patents	Could require a noninfringing production process
Orange Book listings	Could trigger additional Paragraph IV litigation
FDA requirements	Could delay approval independent of patent validity
Bioequivalence	Required successful performance against Suboxone Film
Commercial supply	Required manufacturing capacity and quality compliance
Settlement restrictions	Could limit launch timing if separately agreed
Market competition	Multiple generic entrants could compress pricing

The ’514 decision therefore removed one barrier but did not eliminate every legal or commercial obstacle to generic Suboxone Film entry.

How does this case compare with biosimilar litigation?

The case is a generic small-molecule dispute, not a biosimilar dispute.

Issue	Suboxone Film generic case	Biosimilar case
FDA pathway	ANDA	BLA under section 351(k)
Product type	Small molecule	Biologic
Main regulatory standard	Pharmaceutical equivalence and bioequivalence	Biosimilarity and interchangeability
Patent framework	Hatch-Waxman	BPCIA patent-exchange framework
Key product issue	Formulation, dosage form, bioequivalence	Molecular and clinical similarity
Relevant defendant	Generic drug applicant	Biosimilar sponsor

The case is more relevant to formulation-patent strategy than to biologic patent strategy.

What is the business impact of the Mylan litigation?

Suboxone Film was a major commercial product for Indivior. Generic entry threatened revenue through price erosion, payer substitution, formulary pressure, and loss of market share.

The invalidity ruling had four commercial effects:

1. It reduced the enforceable patent protection around the film formulation.
2. It improved Mylan’s ability to commercialize its ANDA product.
3. It increased the probability of additional generic competition.
4. It lowered the settlement leverage associated with the ’514 patent.

The ruling also affected future patent drafting. Pharmaceutical companies seeking broad formulation claims need support across the full claimed range, not only examples that sit at selected points within that range.

Key Takeaways

• Indivior sued Mylan over its ANDA for generic buprenorphine/naloxone sublingual film.
• The principal patent was U.S. Patent No. 8,603,514.
• The asserted ’514 claims covered a polymer concentration of approximately 40% to 60% by weight.
• The district court held the claims invalid for lack of written-description support.
• The Federal Circuit affirmed the invalidity ruling.
• The decision removed the ’514 patent as a meaningful barrier to Mylan’s generic launch.
• The case involved a small-molecule ANDA, not a biosimilar application.
• The ruling did not invalidate every Indivior patent covering Suboxone Film.
• Separate patents, manufacturing processes, regulatory requirements, and settlements remained relevant to generic entry.
• The case is a leading example of written-description risk in broad formulation-range claims.

FAQs About Indivior v. Mylan

What was Mylan’s generic product in the case?

Mylan sought approval for a generic buprenorphine/naloxone sublingual film equivalent to Suboxone Film through ANDA No. 209657.

Which patent did the Federal Circuit invalidate?

The key patent was U.S. Patent No. 8,603,514. The court affirmed that the asserted claims lacked adequate written-description support for the claimed polymer range.

Did Indivior lose all Suboxone patents?

No. The ruling addressed the asserted claims in the Mylan litigation. It did not automatically invalidate every patent covering Suboxone Film, its manufacture, or its use.

Was the case a biosimilar patent dispute?

No. Suboxone Film is a small-molecule drug. The dispute proceeded under the Hatch-Waxman ANDA framework.

What patent-law issue is most important from the case?

The main issue is whether a patent specification demonstrates possession of the entire numerical formulation range claimed. Narrow examples and separate subranges may not support a materially broader range.

References

1. United States Court of Appeals for the Federal Circuit. (2022). Indivior Inc. v. Mylan Technologies Inc., 40 F.4th 1320.
2. United States District Court for the District of Delaware. (2019). Indivior Inc. v. Mylan Technologies Inc., No. 1:17-cv-00157.
3. United States Patent and Trademark Office. (2005). U.S. Patent No. 8,603,514: Drug-containing polymeric films and methods of making same.
4. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act, Pub. L. No. 98-417, 98 Stat. 1585.